Exploring the impact of variable power outputs on the efficacy and safety during microwave ablation for lung carcinoma: a real-world study

被引:0
|
作者
Cui, Song-Ping [1 ,2 ]
Zhao, Qing [1 ,2 ]
Wang, Jing [1 ,2 ,3 ]
Ji, Ying [1 ,2 ]
Miao, Jin-Bai [1 ,2 ]
Fu, Yi-Li [1 ,2 ]
Hu, Bin [1 ,2 ]
Chen, Shuo [1 ,2 ]
机构
[1] Capital Med Univ, Beijing Inst Resp Med, Dept Thorac Surg, 8 Gongtinan Rd, Beijing 100020, Peoples R China
[2] Capital Med Univ, Beijing Chao Yang Hosp, 8 Gongtinan Rd, Beijing 100020, Peoples R China
[3] Harvard Med Sch, Mass Gen Canc Ctr, Mass Gen Brigham, Boston, MA USA
关键词
Lung carcinoma; microwave ablation (MWA); power; complication; prognosis; CANCER; SURVIVAL; THERAPY;
D O I
10.21037/jtd-24-557
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Microwave ablation (MWA) is an important method for the treatment of lung cancer, but there is still a lack of standard guidelines for the selection of power. This study aimed to explore the effectiveness and safety of MWA at different power levels. Methods: The study gathered individuals underwent MWA for lung cancer between January 2012 and December 2020. All patients were divided into low power group and high power group based on the power of MWA. By intergroup comparisons, we clarified the differences between the two groups. Results: In this study, 265 participants were involved, with 192 in the low power group and 73 in the high power group. Compared to the low power group, the high power group had a significantly higher incidence of postoperative complications (63.0% vs. 24.0%). In the Kaplan-Meier analysis, overall survival (OS) and disease-free survival (DFS) of the high power group were both better than the low power group. We found through Cox regression analysis that smoking, tumor volume, tumor differentiation, gene mutation, neutrophil count, and lymphocyte count were independent factors affecting the OS of patients. Based on the above factors, we constructed a nomogram, with areas under the curve (AUCs) of 0.941, 0.903, and 0.905 for predicting 1-, 2-, and 3-year OS after MWA, respectively. Conclusions: While high-power MWA brings better long-term prognosis to patients, it also leads to an increase in postoperative complications. The application of a nomogram for stratifying the prognosis of patients may be a more feasible approach to further develop individualized treatment plans.
引用
收藏
页码:5031 / 5041
页数:12
相关论文
共 50 条
  • [31] Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta
    Vrdoljak, Eduard
    Magri, Claude
    Gamulin, Marija
    Boskovic, Lidija
    Omrcen, Tomislav
    Bajic, Zarko
    Dienes, Tamas
    Geczi, Lajos
    NEOPLASMA, 2021, 68 (01) : 208 - 215
  • [32] Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
    De Giorgi, Ugo
    Carteni, Giacomo
    Giannarelli, Diana
    Basso, Umberto
    Galli, Luca
    Cortesi, Enrico
    Caserta, Claudia
    Pignata, Sandro
    Sabbatini, Roberto
    Bearz, Alessandra
    Buti, Sebastiano
    Lo Re, Giovanni
    Berruti, Alfredo
    Bracarda, Sergio
    Cognetti, Francesco
    Rastelli, Francesca
    Fornarini, Giuseppe
    Porta, Camillo
    Turci, Daniele
    Sternberg, Cora N.
    Procopio, Giuseppe
    Falcone, A.
    Roila, F.
    Cascinu, S.
    Tirelli, U.
    Giustini, L.
    Sobrero, A.
    Cappuzzo, F.
    Tortora, G.
    Tassinari, D.
    Passalacqua, R.
    Pazzola, A.
    Surico, G.
    Maio, M.
    Benedetti, G.
    Barone, C.
    Adamo, V.
    Ricevuto, E.
    De Censi, A.
    Spada, M.
    Tonini, G.
    Pinto, C.
    Ciuffreda, L.
    Ruggeri, E. M.
    Bengala, C.
    Scotti, V.
    Fagnani, D.
    Bonetti, A.
    Mitterer, M.
    Castiglione, F.
    BJU INTERNATIONAL, 2019, 123 (01) : 98 - 105
  • [33] Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study
    Guo, Yiyu
    Xu, Xinyu
    Wang, Tian
    Liu, Ying
    Gu, Dayong
    Fang, Ying
    Wang, Qiang
    Shi, Haifeng
    Wu, Daguang
    Zhang, Zhi
    Zhou, Guoren
    Ye, Jinjun
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 138
  • [34] Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study
    Hua, Xuefeng
    Yin, Ziwei
    Liang, Jin
    Chen, Wenbin
    Gong, Hui
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (01) : 120 - 128
  • [35] Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
    Ma, Ke
    Guo, Qianqian
    Li, Xingya
    BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [36] Impact of the extent of recurrent laryngeal nerve lymphadenectomy on thoracic esophageal squamous cell carcinoma: a real-world multicentre study
    Xu, Sukai
    Chen, Donglai
    Liu, Zhichao
    Song, Peidong
    Zheng, Yujia
    Xue, Xiang
    Sang, Yonghua
    Li, Zhigang
    Chen, Yongbing
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2023, 63 (05)
  • [37] Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study
    Su, Ruopeng
    Chen, Zeyu
    Hong, Daoping
    Jiang, Shuai
    Yuan, Yichu
    Cai, Xingyun
    Hu, Hailong
    Fu, Changde
    Huang, Zhiyang
    Wang, Zhenyu
    Zheng, Bing
    Huang, Jian
    Wang, Zaoyu
    Bao, Yige
    Cai, Ming
    Guo, Jianming
    Chen, Minfeng
    Wei, Qiang
    Huang, Jiwei
    Xue, Wei
    CANCER MEDICINE, 2023, 12 (09): : 10587 - 10596
  • [38] Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study
    Feng, Jin-Kai
    Sun, Ju-Xian
    Liu, Zong-Han
    Gu, Jing-Wen
    Chen, Zhen-Hua
    Liu, Chang
    Guo, Wei-Xing
    Shi, Jie
    Cheng, Shu-Qun
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 3551 - 3560
  • [39] Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study
    You, Ran
    Xu, Qingyu
    Wang, Qi
    Zhang, Qingqiao
    Zhou, Weizhong
    Cao, Chi
    Huang, Xiangzhong
    Ji, Honghai
    Lv, Penghua
    Jiang, Hao
    Lu, You
    Jin, Yong
    Li, Yongjun
    Cheng, Long
    Wang, Weidong
    Xu, Hao
    Zhu, Xiaoli
    Yin, Guowen
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [40] Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
    Yoo, Changhoon
    Im, Hyeon-Su
    Kim, Kyu-pyo
    Oh, Do-Youn
    Lee, Kyung-Hun
    Chon, Hong Jae
    Kim, Joo Hoon
    Kang, Myoungjoo
    Kim, Ilhwan
    Lee, Guk Jin
    Oh, Sung Yong
    Choi, Younak
    Choi, Hye Jin
    Kim, Seung Tae
    Park, Joon Oh
    Ryoo, Baek-Yeol
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11